Minocycline compounds and methods of use thereof
View Patent ↗Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, B - streptococci , Viridans Streptococci, Enterococcus , or combinations thereof.
1. A method of treating a human subject for complicated Skin and Skin Structure Infections, comprising intravenously administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein gastrointestinal (GI) adverse events (AEs) associated with treatment are mild.
2. The method of claim 1 , wherein said salt is a hydrochloride salt.
3. The method of claim 1 , wherein said salt is a tosylate salt.
4. The method of claim 1 , wherein said subject is suffering from injury, major abscess, or cellulitis.
5. The method of claim 4 , wherein said injury is a traumatic injury.
6. The method of claim 1 , wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered intravenously at a dose of about 50 mg to about 150 mg per day.
7. The method of claim 6 , wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered intravenously at a dose of about 100 mg per day.
8. The method of claim 1 , wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline has a clinical success rate of treating an infection of greater than about 93.2%.
9. The method of claim 1 , wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline has a microbiologically evaluable clinical success rate of treating an infection of greater than about 93.7%.
10. The method of claim 1 , wherein said skin and skin structure infections are caused by Staphylococcus aureus, Streptococci , or a combination thereof.
11. The method of claim 10 , wherein said Staphylococcus aureus is methicillin-resistant Staphylococcus aureus (MRSA), or methicillin-susceptible Staphylococcus aureus (MSSA).
12. The method of claim 10 , wherein said Streptococci is beta Streptococci.
13. The method of claim 10 , wherein said Streptococci is Streptococcus pyogenes.
14. The method of claim 1 , wherein said skin and skin structure infections are characterized by the presence of one or more of erythema, edema, and induration.
15. The method of claim 1 , wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered once per day.
16. The method of claim 1 , wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered intravenously, followed by an oral administration.
17. The method of claim 16 , wherein said subject is treated up to and including about 14 days, up to and including about 10 days, up to and including about 9 days, up to and including about 8 days, or up to and including about 7 days, such that said subject is treated.
18. The method of claim 16 , wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered intravenously by up to 7 days, followed by about 1 week or about 2 weeks of oral administration.
19. The method of claim 18 , wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered intravenously for about 4 days, and total treatment period including intravenous and oral administration is about 10 days.
20. The method of claim 1 , wherein GI adverse events (AEs) associated with treatment do not result in discontinuation of therapy.